Silo pharma and resyca bv partner on device and cmc development for intranasal ptsd drug spc-15

Nose-to-brain drug delivery shows promising patient safety and therapeutic benefit the device and cmc development master plan is designed to support ind-enabling studies sarasota, fl, july 18, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a device and cmc development master plan with resyca bv, a medical technology provider. resyca is a joint venture between bespak group and medspray pharma bv which manufactures the formulation-specific microchip-based spray system chosen by silo for its lead candidate spc-15, an intranasal prophylactic treatment for post-traumatic stress disorder (ptsd).
SILO Ratings Summary
SILO Quant Ranking